REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers Portfolio News / By admin July 9, 2019 REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers Read More »
ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific Officer Portfolio News / By admin July 9, 2019 ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific Officer Read More »
Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer Portfolio News / By admin June 24, 2019 Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer Read More »
RAPT Therapeutics (Formerly FLX Bio) Completes $37 Million Series C Extension Portfolio News / By admin June 18, 2019 RAPT Therapeutics (Formerly FLX Bio) Completes $37 Million Series C Extension Read More »
Exonics Therapeutics Acquired by Vertex, Expanding into New Disease Areas and Enhances Gene Editing Capabilities Portfolio News / By admin June 6, 2019 Exonics Therapeutics Acquired by Vertex, Expanding into New Disease Areas and Enhances Gene Editing Capabilities Read More »
Constellation’s Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients Portfolio News / By admin June 3, 2019 Constellation’s Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients Read More »
FLX Bio Announces Name Change to RAPT Therapeutics Portfolio News / By admin May 24, 2019 FLX Bio Announces Name Change to RAPT Therapeutics Read More »
Peloton Therapeutics Acquired by Merck, Bolstering Oncology Pipeline Portfolio News / By admin May 21, 2019 Peloton Therapeutics Acquired by Merck, Bolstering Oncology Pipeline Read More »
ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer Portfolio News / By admin May 13, 2019 ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer Read More »
Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer Portfolio News / By admin May 2, 2019 Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer Read More »
